Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Current Deferred Revenue (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Current Deferred Revenue over the past 14 years, most recently at $9.0 million for Q4 2024.

  • For Q4 2024, Current Deferred Revenue rose 4.73% year-over-year to $9.0 million; the TTM value through Nov 2024 reached $9.0 million, up 4.73%, while the annual FY2024 figure was $10.6 million, 51.28% up from the prior year.
  • Current Deferred Revenue for Q4 2024 was $9.0 million at Lifecore Biomedical, Inc. \De\, down from $9.3 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $10.6 million in Q2 2024 and troughed at $287000.0 in Q2 2021.
  • A 5-year average of $3.6 million and a median of $1.1 million in 2021 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 51.94% in 2020 and later soared 1150.81% in 2023.
  • Year by year, Current Deferred Revenue stood at $297000.0 in 2020, then soared by 225.59% to $967000.0 in 2021, then dropped by 24.41% to $731000.0 in 2022, then soared by 1076.47% to $8.6 million in 2023, then rose by 4.73% to $9.0 million in 2024.
  • Business Quant data shows Current Deferred Revenue for LFCR at $9.0 million in Q4 2024, $9.3 million in Q3 2024, and $10.6 million in Q2 2024.